MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
ChromaDex Corporation DPO Ratio 2011-2026 | CDXC
Annual DPO Ratio ChromaDex Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.3 | 90.1 | 111 | 125 | 140 | 144 | 171 | 225 | 127 | 168 | 126 | - | 74.8 | 134 | 40.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 225 | 40.3 | 125 |
Quarterly DPO Ratio ChromaDex Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 | 102 | 78.4 | - | 73.3 | 80.7 | 95.1 | - | 117 | 109 | 94 | - | 129 | 136 | 137 | - | 141 | 143 | 177 | - | 151 | 139 | 144 | - | 166 | 181 | 184 | - | 232 | 220 | 176 | - | 107 | 161 | 253 | - | 263 | 116 | 111 | - | 79.8 | 72.1 | 36.1 | - | 87.7 | 86.9 | 73.4 | - | 66.8 | 75.3 | 134 | - | 132 | 164 | 108 | - | 151 | 151 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 263 | 36.1 | 130 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.88 | -1.73 % | $ 6.47 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.48 | 0.81 % | $ 3.73 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
CASI Pharmaceuticals
CASI
|
123 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.06 | -0.98 % | $ 434 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.08 | -1.45 % | $ 2.94 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.49 | 4.58 % | $ 397 M | Britain |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.7 | -1.45 % | $ 114 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
306 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
34.2 K | $ 1.06 | -3.21 % | $ 12.9 M | USA |